At this time, patents and exclusivity rights prevent a generic Votrient (pazopanib) from being manufactured in the United States. The first patent is scheduled to expire in December 2021, which would be the earliest date that a generic version might become available. However, lawsuits, other patents for new uses of the drug, or various other circumstances could delay this.
Can I Buy Generic Votrient?
Votrient® (pazopanib) is a prescription medication used to treat advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma (cancer of the soft tissues, such as the muscle, tendons, and fat). It belongs to a group of medicines called tyrosine kinase inhibitors.
Votrient is made by GlaxoSmithKline. It is currently under the protection of a patent and exclusivity rights that prevent any generic Votrient from being manufactured in the United States.
When Will a Generic Version Be Available?
The first patent for Votrient is set to expire in December 2021. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or shorten this exclusivity period. This includes such things as lawsuits or other patents for specific Votrient uses. Once the patents and exclusivity rights expire, there may be several companies that manufacture a generic Votrient drug.
Is Pazopanib a Generic Votrient?
No, pazopanib is the active ingredient in Votrient, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name." The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Votrient [package insert]. Research Triangle Park, NC: GlaxoSmithKline;2013 August.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed October 7, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click